The Company believes that the Diagen technology should be the first accurate and direct diagnostic for CFS, thus creating the stage for immediate medical treatments. Currently, CFS diagnosis is a costly process of elimination.
Patients undergo a battery of tests to rule out other diseases.
Diagen is a single test, therefore making diagnosis is quicker and overall less expensive than the current diagnostic path. The Company is currently reviewing options for distribution within these countries and expects that the test will be available in the near future. CFS is a multisystem syndrome characterized by months of debilitating fatigue frequently associated with myalgia, headache, sore throat, low grade fever, and tender lymph nodes. The illness interferes with everyday simple tasks such as walking, driving, and remembering appointments. In severe cases, it causes patients to become bedridden.